| Zeit | Aktuelle Nachrichten
| | Leser | Medien |
|---|
| 18.05.
| Psivida Corp Company Reports - Other | | 19 | wotnews |
| 17.05.
| pSivida Corp. Announces Expiration of 2.7 Million Warrants | | 48 | Business Wire |
| pSivida Corp. (NASDAQ: PSDV) (ASX: PVA), a leader in developing
sustained release, drug delivery products for treatment of
back-of-the-eye diseases, today announced the...
Mehr lesen zu:
pSivida Corp. Announces Expiration of 2.7 Million Warrants | |
| 11.05.
| Psivida Corp Company Reports - Yearly | | 14 | wotnews |
| 10.05.
| Psivida Corp Exploration Update | | 16 | wotnews |
| 09.05.
| pSivida Corp. Reports Results for the Third Quarter Ended March 31, 2012 | | 49 | Business Wire |
| pSivida Corp. (NASDAQ: PSDV) (ASX: PVA), a leader in developing
sustained release, drug delivery products for treatment of
back-of-the-eye diseases, today announced financial...
Mehr lesen zu:
pSivida Corp. Reports Results for the Third Quarter Ended March 31, 2012 | |
| 08.05.
| pSivida Corporation nears sales of ILUVIEN® in the U.K. with granting of marketing approval | | 21 | Proactive Investors |
| 08.05.
| Psivida Corp Company Reports - Other | | 3 | wotnews |
| 07.05.
| pSivida (PSDV) Gets MHRA MAA Approval for ILUVIEN in Europe | | 11 | StreetInsider.com |
| 07.05.
| pSivida Corp. Announces United Kingdom Grants ILUVIEN® Marketing Authorization for the Treatment of Chronic Diabetic Macular Edema | | 132 | Business Wire |
| pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in developing sustained
release, drug delivery products for treatment of back-of-the-eye
diseases, today announced the...
Mehr lesen zu:
pSivida Corp. Announces United Kingdom Grants ILUVIEN® Marketing Authorization for the Treatment of Chronic Diabetic Macular Edema | |
| 03.05.
| pSivida Corp Announces Third Quarter 2012 Financial Results Release Date and Conference Call Information | | 46 | Business Wire |
| pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in developing sustained
release, drug delivery products for treatment of back-of-the-eye
diseases, today announced that...
Mehr lesen zu:
pSivida Corp Announces Third Quarter 2012 Financial Results Release Date and Conference Call Information | |
| 26.04.
| Psivida Corp Company Reports - Other | | 29 | wotnews |
| 24.04.
| pSivida (PSDV) Gets MAA Approval for ILUVIEN in Austria | | 13 | StreetInsider.com |
| 24.04.
| pSivida Corp. Announces ILUVIEN Receives Marketing Authorization in Austria for the Treatment of Chronic Diabetic Macular Edema | | 5 | Benzinga.com |
| 24.04.
| pSivida Corp. Announces ILUVIEN® Receives Marketing Authorization in Austria for the Treatment of Chronic Diabetic Macular Edema | | 57 | Business Wire |
| pSivida Corp. (NASDAQ: PSDV)(ASX: PVA), a leader in developing sustained
release, drug delivery products for treatment of back-of-the-eye
diseases, today announced the...
Mehr lesen zu:
pSivida Corp. Announces ILUVIEN® Receives Marketing Authorization in Austria for the Treatment of Chronic Diabetic Macular Edema | |
| 28.03.
| Psivida Corp Company Reports - Other | | 74 | wotnews |
| 13.03.
| pSivida Announces Second Tech Evaluation Agreement with its BioErodible Durasert Technology | | 48 | Business Wire |
| Agreement
with Neuron Systems Focuses on Dry AMD
pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in developing sustained
release, drug delivery...
Mehr lesen zu:
pSivida Announces Second Tech Evaluation Agreement with its BioErodible Durasert Technology | |
| 07.03.
| Psivida Corp Company Reports - Other | | 30 | wotnews |
| 06.03.
| pSivida Corp. Names Douglas Godshall to Board of Directors | | 32 | Business Wire |
| pSivida Corp. (NASDAQ: PSDV)(ASX: PVA), a leader in developing sustained
release, drug delivery products for treatment of back-of-the-eye
diseases, announced today that...
Mehr lesen zu:
pSivida Corp. Names Douglas Godshall to Board of Directors | |
| 28.02.
| pSivida (PSDV) Gets Positive DCP Outcome for ILUVIEN Approval in Europe | | 65 | StreetInsider.com |
| 28.02.
| pSivida Corp. Announces Positive Outcome to European Decentralized Procedure for Approval of ILUVIEN® for the Treatment of Chronic Diabetic Macular Edema | | 106 | Business Wire |
| ILUVIEN® expected to be the first sustained release pharmaceutical
in the European Union (EU) to treat diabetic macular edema (DME)
ILUVIEN...
Mehr lesen zu:
pSivida Corp. Announces Positive Outcome to European Decentralized Procedure for Approval of ILUVIEN® for the Treatment of Chronic Diabetic Macular Edema | |
